Visit booth 106 to learn how Covalon is
leading the charge with compassion driven innovation through
gentler infection prevention solutions.
MISSISSAUGA, ON, March 20,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced its participation in the
Synova NICU Leadership Forum from Sunday,
March 19 to Thursday, March 23,
2023 in Tuscon, Arizona.
Clinicians looking for more compassionate care solutions that help
prevent infection, improve patient outcomes, and reduce stress on
care providers should visit Covalon at booth 106 to learn more
about Covalon's unique position to offer "apology-free", tender,
and atraumatic IV dressing changes, as well catheter hub and line
connection protection, for NICU and pediatric patients.
"Here at Covalon, courageous leadership means prioritizing
compassion, even amongst competing priorities and limited
resources, so that all patients, but especially the youngest,
experience the care and comfort they deserve," said Ron Hebert, Senior Vice President, Global
Marketing, Covalon. "We're excited to be attending Synova NICU
Leadership Forum for the first time so that clinicians and leaders
can see, feel, and experience how our compassionate care solutions
can help even the tiniest patients."
At this year's Synova NICU Leadership Forum, Covalon is taking
up the conference theme "Fearless: Choosing to Lead with Courage,"
by asking conference attendees to experience the difference
compassion driven innovation can make in a vascular access dressing
and line guard for NICU patients.
At booth 106, Covalon will be demonstrating how critical the
intersection between medical devices, the caregiver-patient
relationship, and compassion is to driving positive patient
outcomes. Inspired by lived experience and created to protect,
heal, and comfort pediatric patients, Covalon's solutions are
redefining the standards of care that come with vascular access
technology designed for children. Today, 6 of the top 10 children's
hospitals, as ranked by U.S. News & World Report, have adopted
Covalon's uniquely designed compassionate care solutions.
- CovaClear® IV – utilizes soft silicone adhesive
technology to help protect patients from skin injuries, but does
not incorporate antimicrobials, for use with patients who either
don't require or cannot tolerate antimicrobials.
- VALGuard® - an FDA listed, transparent,
environmental barrier designed to protect catheter hubs and line
connections from external contaminants and gross contamination,
including body fluids and other secretions. It incorporates a
quick-release pull strip for fast access to infusion hubs and for
easy removal.
- IV Clear® - the world's only dual-antimicrobial
vascular access dressing that offers complete transparency at and
around the insertion site for easy daily assessment. It also
utilizes soft silicone adhesive technology to minimize skin
injuries and preserve skin barrier functions, and incorporates safe
amounts of antimicrobials, without sacrificing efficacy, to protect
against chemical irritation.
- SurgiClear® - the world's only
dual-antimicrobial clear postoperative dressing that provides full
surgical site visibility, allowing for visual site inspection and
thus eliminating the need for early and multiple dressing
removals.
Conference details
Dates: Saturday, March 19 to
Thursday, March 23, 2023
Venue: Westin La Paloma, Tuscon,
Arizona
Website: https://www.synovaassociates.com/nicu-leadership-forum
For healthcare providers who are not able to attend the
conference but are interested in learning more about Covalon's
solutions, visit www.covalon.com or follow Covalon on LinkedIn,
Facebook, Instagram, or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results "may",
"could", "would", "might", "will" or "will be taken", "occur", or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which
is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leader-in-compassionate-care-infection-prevention-solutions-covalon-to-participate-in-the-synova-nicu-leadership-forum-2023-in-tucson-arizona-from-march-19-to-23-2023-301775530.html
SOURCE Covalon Technologies Ltd.